Sort   by:  
 Page size 

Importance

In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months.

Objective

To evaluate the efficac...

Background

The majority of NSTEMI burden resides outside high-income countries (HICs). We describe presentation, care, and outcomes of NSTEMI by country income classification.

Methods and results

Prospective cohort study including 2947 patients with NSTEMI from 287 centres in 59 count...
Sort   by:  
 Page size